Literature DB >> 180465

Serum testosterone and dihydrotestosterone in patients with trophoblastic disease.

M Y Dawood, B B Saxena.   

Abstract

Serum testosterone (T) and dihydrotestosterone (DHT) were measured by radioimmunoassay in 14 patients with unaborted hydatidiform mole and in 16 patients with normal pregnancy of similar gestational age. Serum human chorionic gonadotropin (hCG) was measured by the radioreceptor assay in patients with hydatidiform mole. Serum T ranged from 0.27 to 5.39 ng/ml with a mean +/- SE of 2.21 +/- 0.45 ng/ml in patients with hydatidiform mole mole and from 0.20 to 2.40 ng/ml with a mean +/- SE of 0.80 +/- 0.14 ng/ml in patients with normal pregnancy, the difference being statistically significant (P = less than 0.005). Similarly, patients with molar pregnancies had a significantly higher (P = less than 0.005) serum DHT (range: 0.09 to 0.62 ng/ml; mean +/- SE: 0.29 +/- 0.05 ng/ml) than patients with normal pregnancies (range: 0.04 to 0.28 ng/ml; mean +/- SE 0.12 +/- 0.02 ng/ml). There was no significant correlation between uterine size or serum hCG and serum T or DHT. The possible sources of the elevated serum T and DHT and the lack of hirsutism or virilization in patients with trophoblastic disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180465

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Marital sex frequency and midcycle female testosterone.

Authors:  N M Morris; J R Udry; F Khan-Dawood; M Y Dawood
Journal:  Arch Sex Behav       Date:  1987-02

2.  Ovarian and adrenal androgens and their link to high human chorionic gonadotropin levels: a prospective controlled study.

Authors:  René Rodríguez-Gutiérrez; Jesús Zacarías Villarreal-Pérez; Felipe Arturo Morales-Martinez; René Rodríguez-Guajardo; Gloria González-Saldivar; Leonardo G Mancillas-Adame; Neri Alejandro Alvarez-Villalobos; Fernando Javier Lavalle-Gonzalez; José Gerardo González-González
Journal:  Int J Endocrinol       Date:  2014-11-23       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.